Augustine Asset Management Inc. Has $2.13 Million Holdings in Sanofi $SNY

Augustine Asset Management Inc. reduced its stake in Sanofi (NASDAQ:SNY) by 41.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 45,158 shares of the company’s stock after selling 32,334 shares during the quarter. Augustine Asset Management Inc.’s holdings in Sanofi were worth $2,131,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of SNY. Thomasville National Bank lifted its position in Sanofi by 0.3% in the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after purchasing an additional 211 shares during the period. HM Payson & Co. raised its position in shares of Sanofi by 3.4% during the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after acquiring an additional 235 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its holdings in Sanofi by 4.7% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock valued at $252,000 after buying an additional 238 shares during the period. CreativeOne Wealth LLC lifted its stake in Sanofi by 2.8% in the second quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock valued at $434,000 after buying an additional 241 shares during the period. Finally, U.S. Capital Wealth Advisors LLC raised its holdings in Sanofi by 4.1% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock worth $301,000 after purchasing an additional 247 shares during the period. Institutional investors own 14.03% of the company’s stock.

Sanofi Trading Down 1.5%

Shares of Sanofi stock opened at $47.51 on Tuesday. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a market capitalization of $115.88 billion, a P/E ratio of 11.13, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45. The stock has a fifty day simple moving average of $49.40 and a 200 day simple moving average of $48.87. The company has a current ratio of 1.06, a quick ratio of 0.30 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 24th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $1.60 by $1.31. The firm had revenue of $15.46 billion during the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same quarter last year, the business posted $2.25 EPS. On average, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SNY shares. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Cowen reaffirmed a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.